CRS Clinical Research Services’ Post

Explore the intricacies of clinical trial participant payments with IQVIA leader Shaun Williams in this Applied Clinical Trials Magazine webinar. Join us to discuss a new approach to managing participant payments. Register now: https://bit.ly/4bXRoT9 #ClinicalPayments #ClinicalTrials

Key stakeholders, including the American Hospital Association (AHA), AdvaMedDx, and the American Clinical Laboratory Association (ACLA), are weighing in on the regulation of diagnostic tests, particularly laboratory-developed tests (LDTs). Senator Bill Cassidy's inquiry has sparked this conversation around diagnostics regulation. While opinions differ, many express a preference for legislative action over a regulatory overhaul led by the FDA. Stakeholders emphasize the need for modernized oversight tailored to the unique nature of diagnostics to ensure patient access to innovative and reliable tests. Stay informed on the latest developments in healthcare policy and the regulation of diagnostics. #Diagnostics #Regulation #HealthcarePolicy

Read about the Linical strategy to insuring a speedy and accurate start up phase for your clinical trial. Finding the right sites, getting them quickly activated and keeping them motivated are critical factors for the success of your trial.

Discover how CTB is saving time and money for everyone involved in clinical trials! ⏱️💰 See for yourself why CTB is the go-to platform for reducing costs and accelerating clinical trials. 👉 Watch the video and follow us to learn how CTB can support your clinical trials. #businesssolutions #ctb #clinicaltrials #costsavings #timemanagement #researchplatform #clinicalresearch #healthcareinnovation #clinicalsolutions

New article now live! The start up phase of any clinical trial is critically important. Linical explains how study start up and site activation strategies can impact the direction of your clinical trial. Read more. » https://hubs.la/Q02P897D0 #clinicaltrials #clinicaldevelopment #studystartup #siteactivation #linicalCRO

CPME, the Standing Committee of European Doctors, supports the set up and maintenance of national registers of transfers of value between doctors and healthcare industry. https://lnkd.in/eDXGW4xb

Clinical trial diversity and representative enrollment efforts can be a daunting subject to start a conversation about. I created a starting guide with actionable steps that we as clinical trial professionals can bring to the table when planning studies, and talking about ID&E efforts. If we all take step one together we can build a better way forward for all our subjects and patients. The FDA has an open comment period on a draft guidance on this topic closing September 26th, 2024.If you have questions or want to expand on any of the ideas in this guide, please feel free to comment/DM and let's have that conversation. #clinicalresearch #representativeenrollment #medicaldevice #thisispublichealth #accesstocare #parkinsonsdisease #clinicaltrialdiversity #fda #fdaguidance Design credit: Jordan Rastall

At ICON, we believe that the best clinical trials are those that focus on outcomes that truly matter to patients. Our new Outcome Measures solution helps sponsors leverage DHTs and COAs to collect real-world data that reflects patients' daily experiences. Read our latest blog post to learn how this solution can support regulatory approval. https://ow.ly/ZrzB50Tl4Iq #ClinicalInnovation #PatientCentredTrials #OutcomeMeasures

Clinical trial Sponsors are hyper-focused on compressing clinical trial cycle times; looking for efficiencies and innovations that can remove months, or even years, from the process. We all have the same end goal – to help get treatments to patients faster! With that motivation in mind, read what Diligent has to say about “Navigating the Fast Lane: Five Strategies to Accelerate Clinical Trials.” Download now: https://lnkd.in/d4DgCz3q #ClinicalTrials #VendorQualification #ClinicalResearch #AuditModernization

Traditionally, the FDA has relied heavily on clinical trials to gather evidence. However, in recent years, the FDA has increasingly turned to Real-World Evidence (RWE) to complement clinical trial data, making the regulatory process more robust and reflective of actual patient experiences. In this blog, we’ll discuss how the FDA uses RWE and its impact on healthcare innovation and patient safety. Read more here: https://lnkd.in/eeNKAHvx